04/08/2024
5:44 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/12/2024
7:34 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
|
03/12/2024
7:40 AM | Inozyme Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/12/2024
7:32 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
6:11 PM | Inozyme Pharma (Subject)
Sofinnova Venture Partners X, L.P. (Filed by)
| Form SC 13D/A | |
02/14/2024
7:34 PM | Inozyme Pharma (Subject)
Venrock Healthcare Capital Partners II, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
5:08 PM | Inozyme Pharma (Subject)
New Enterprise Associates 15, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
12:40 PM | Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
| Form SC 13G | |
02/14/2024
10:54 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
02/14/2024
7:48 AM | Deep Track Capital, LP (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
02/12/2024
8:06 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
02/07/2024
6:46 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
02/05/2024
8:12 AM | Inozyme Pharma (Subject)
SPHERA FUNDS MANAGEMENT LTD. (Filed by)
| Form SC 13G/A | |
11/15/2023
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
11/07/2023
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/07/2023
7:34 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
09/26/2023
3:12 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2023
7:37 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2023
8:03 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/07/2023
8:58 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
08/03/2023
7:01 PM | Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/03/2023
7:13 PM | Inozyme Pharma (Issuer)
Pivotal bioVenture Partners Fund I G.P., L.P. (Reporting)
Pivotal bioVenture Partners Fund I U.G.P. Ltd (Reporting)
Pivotal bioVenture Partners Fund I, L.P. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/28/2023
4:17 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
07/28/2023
4:19 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/27/2023
4:28 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
06/27/2023
3:05 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/15/2023
3:16 PM | Inozyme Pharma (Issuer)
Mathers Edward T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2023
3:36 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/31/2023
3:17 PM | Inozyme Pharma (Subject)
MILLENNIUM MANAGEMENT LLC (Filed by)
| Form SC 13G | |
05/23/2023
3:48 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
05/09/2023
7:43 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/09/2023
7:35 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/03/2023
7:40 AM | Bolte Axel (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
